The EU, whose member states are far behind Israel, Britain and the
United States in rolling out vaccines, is scrambling to get supplies
just as the West’s biggest drugmakers slow deliveries to the bloc
due to production problems.
AstraZeneca said last week it would cut deliveries in the first
quarter due to production issues at a Belgian factory. An EU
official said that meant the EU would receive 31 million doses in
the period, or 60% less than initially agreed.
In a bid to break the deadlock, AstraZeneca offered 8 million more
doses of its shot to the EU, but the bloc said that was too far
short of what was originally promised, an EU official told Reuters.
Under a contract agreed in August, the company should have supplied
at least 80 million doses to the EU in that period, the official
said, and possibly even 120 million "depending on how you read the
contract".
EU Commission head Ursula von der Leyen urged AstraZeneca to fulfil
its obligations and said it had paid the company in advance.
"There are binding orders and the contract is crystal clear," she
told Deutschlandfunk radio, adding it contained the amount of doses
for December and the first three quarters of 2021.
AstraZeneca has published its contract with the European Commission,
the executive body said on Friday. It was signed on Aug. 27 last
year and largely redacted, but von der Leyen said it mentioned four
delivery sites, two of which were in Britain. (https://bit.ly/2MBIaoU)
AstraZeneca Chief Executive Pascal Soriot told newspapers on Tuesday
the EU contract was based on a "best-effort" clause and did not
commit the company to a specific timetable.
Soriot has also said the EU was late to strike a supply contract so
the company did not have enough time to iron out production problems
at a vaccine factory run by a partner in Belgium.
Von der Leyen said the "best-effort" clause was only valid as long
as it was not clear whether AstraZeneca could develop a vaccine. She
also said commitments with other buyers should not affect the order
in which supplies are delivered.
[to top of second column] |
Britain, in turn, said it could
not publish details of its AstraZeneca COVID-19
supply contract because it would jeopardize
national security, a junior minister said on
Friday.
EU APPROVAL EXPECTED
Drug makers across the world have developed
vaccines in less than a year, with many already
approved by regulators, super-fast progress by
comparison with previous viruses, and glitches
in production and delivery had always been
expected. The European Medicines
Agency is expected to approve the AstraZeneca vaccine later on
Friday, making it the third shot available in the bloc.
The head of Germany's vaccine regulator, Paul Cichutek, told a news
conference he expected the vaccine to be approved without age
restrictions with the warning that the amount of available data for
older age groups was limited. Germany's vaccine
committee said on Wednesday it could only recommend the shot for
those aged under 65, although Health Minister Jens Spahn said the
final recommendation would only come once the shot was approved.
The EU contract with AstraZeneca is an advance purchase agreement
for the supply of at least 300 million doses provided the vaccine is
approved as safe and effective, with doses delivered in stages.
The EU has also faced cuts to vaccine deliveries from Pfizer and
German partner BioNTech, pilling pressure on policymakers who are
facing criticism from voters over the sluggish pace of the rollout.
In a further headache for the bloc, France and Italy said they were
getting fewer COVID-19 vaccine doses produced by Moderna than
promised.
France expects 25% fewer doses than previously anticipated, the
health ministry said on Thursday, while Italy's COVID-19 special
commissioner said on Friday that Moderna would deliver 20% fewer
vaccines to Italy in the week starting on Feb. 7.
(Additional reporting by Sabine Siebold in Brussels and Sarah Young
in London; Editing by Maria Sheahan, Mark Potter and Nick Macfie)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |